D. Western Therapeutics Institute, Inc. provided earnings guidance for the fiscal year ending December 31, 2022. The company expects net sales to be JPY 370 million, Operating loss to be JPY 690 million, loss attributable to owners of parent to be JPY 670 million or JPY 22.82 per basic share.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
109 JPY | +3.81% | +0.93% | -22.70% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.70% | 21.74M | |
+3.91% | 109B | |
+10.87% | 105B | |
+0.44% | 22.25B | |
-13.14% | 22.09B | |
-8.12% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- 4576 Stock
- News D. Western Therapeutics Institute, Inc.
- D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022